{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:01:44Z","timestamp":1791939704800,"version":"4.3.4"},"reference-count":44,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010662","name":"H2020 Excellent Science","doi-asserted-by":"publisher","award":["764281"],"award-info":[{"award-number":["764281"]}],"id":[{"id":"10.13039\/100010662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","award":["CAN 2017\/685"],"award-info":[{"award-number":["CAN 2017\/685"]}],"id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2015-04622"],"award-info":[{"award-number":["2015-04622"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20160265"],"award-info":[{"award-number":["20160265"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["K0138-2015"],"award-info":[{"award-number":["K0138-2015"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","award":["12\/12-2017"],"award-info":[{"award-number":["12\/12-2017"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2-3591\/2014"],"award-info":[{"award-number":["2-3591\/2014"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2018-02153"],"award-info":[{"award-number":["2018-02153"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2014-424"],"award-info":[{"award-number":["CAN 2014-424"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["161 052"],"award-info":[{"award-number":["161 052"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["181173"],"award-info":[{"award-number":["181173"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["2018-00938"],"award-info":[{"award-number":["2018-00938"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","award":["H Eriksson 2016"],"award-info":[{"award-number":["H Eriksson 2016"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-684391"],"award-info":[{"award-number":["SLS-684391"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r Strategisk Forskning","doi-asserted-by":"publisher","award":["RIF14-0046"],"award-info":[{"award-number":["RIF14-0046"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have significantly improved the outcome in metastatic cutaneous melanoma (CM). However, therapy response is limited to subgroups of patients and clinically useful predictive biomarkers are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To discover treatment-related systemic changes in plasma and potential biomarkers associated with treatment outcome, we analyzed serial plasma samples from 24 patients with metastatic CM, collected before and during ICI treatment, with mass-spectrometry-based global proteomics (high-resolution isoelectric focusing liquid chromatography\u2013mass spectrometry (HiRIEF LC-MS\/MS)) and targeted proteomics with proximity extension assays (PEAs). In addition, we analyzed plasma proteomes of 24 patients with metastatic CM treated with mitogen-activated protein kinase inhibitors (MAPKis), to pinpoint changes in protein plasma levels specific to the ICI treatment. To detect plasma proteins associated with treatment response, we performed stratified analyses in anti-programmed cell death protein 1 (anti-PD-1) responders and non-responders. In addition, we analyzed the association between protein plasma levels and progression-free survival (PFS) by Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Unbiased HiRIEF LC-MS\/MS-based proteomics showed plasma levels\u2019 alterations related to anti-PD-1 treatment in 80 out of 1160 quantified proteins. Circulating PD-1 had the highest increase during anti-PD-1 treatment (log2-FC=2.03, p=0.0008) and in anti-PD-1 responders (log2-FC=2.09, p=0.005), but did not change in the MAPKis cohort. Targeted, antibody-based proteomics by PEA confirmed this observation. Anti-PD-1 responders had an increase in plasma proteins involved in T-cell response, neutrophil degranulation, inflammation, cell adhesion, and immune suppression. Furthermore, we discovered new associations between plasma proteins (eg, interleukin 6, interleukin 10, proline-rich acidic protein 1, desmocollin 3, C-C motif chemokine ligands 2, 3 and 4, vascular endothelial growth factor A) and PFS, which may serve as predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We detected an increase in circulating PD-1 during anti-PD-1 treatment, as well as diverse immune plasma proteomic signatures in anti-PD-1 responders. This study demonstrates the potential of plasma proteomics as a liquid biopsy method and in discovery of putative predictive biomarkers for anti-PD-1 treatment in metastatic CM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2019-000204","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T06:15:31Z","timestamp":1590473731000},"page":"e000204","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":65,"title":["In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01909453","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01584648","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02599402","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-0005","authenticated-orcid":false,"given":"Haris","family":"Baba\u010di\u0107","sequence":"first","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Lehti\u00f6","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Pico de Coa\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pernemalm","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"},{"name":"Theme Cancer\/Department of Oncology\/Skin Cancer Centre, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"2025100303202800000_8.1.e000204.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"2025100303202800000_8.1.e000204.2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-Year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100303202800000_8.1.e000204.3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025100303202800000_8.1.e000204.4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30388-2"},{"key":"2025100303202800000_8.1.e000204.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100303202800000_8.1.e000204.6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100303202800000_8.1.e000204.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065"},{"key":"2025100303202800000_8.1.e000204.8","doi-asserted-by":"crossref","unstructured":"Fridman WH , Pages F , Sautes-Fridman C , et al . The immune contexture in human tumours: impact on clinical outcome. vol. 12, nature reviews. Cancer. England 2012:298\u2013306.","DOI":"10.1038\/nrc3245"},{"key":"2025100303202800000_8.1.e000204.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2025100303202800000_8.1.e000204.10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","article-title":"Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence","volume":"179","author":"Harel","year":"2019","journal-title":"Cell"},{"key":"2025100303202800000_8.1.e000204.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw016"},{"key":"2025100303202800000_8.1.e000204.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0561-9"},{"key":"2025100303202800000_8.1.e000204.13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"Uvb-Induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"2025100303202800000_8.1.e000204.14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41608","article-title":"In-Depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta","volume":"8","author":"Pernemalm","year":"2019","journal-title":"Elife"},{"key":"2025100303202800000_8.1.e000204.15","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2732"},{"key":"2025100303202800000_8.1.e000204.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192"},{"key":"2025100303202800000_8.1.e000204.17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"2025100303202800000_8.1.e000204.18","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"2025100303202800000_8.1.e000204.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100303202800000_8.1.e000204.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03311-y"},{"key":"2025100303202800000_8.1.e000204.21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jso.25138","article-title":"Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma","volume":"118","author":"Kanatsios","year":"2018","journal-title":"J Surg Oncol"},{"key":"2025100303202800000_8.1.e000204.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08123-8","article-title":"Cd73 expression on effector T cells sustained by TGF-\u03b2 facilitates tumor resistance to anti-4-1BB\/CD137 therapy","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"key":"2025100303202800000_8.1.e000204.23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.5093","article-title":"CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment","volume":"245","author":"Enninga","year":"2018","journal-title":"J Pathol"},{"key":"2025100303202800000_8.1.e000204.24","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0272-z"},{"key":"2025100303202800000_8.1.e000204.25","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0290-x"},{"key":"2025100303202800000_8.1.e000204.26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0288"},{"key":"2025100303202800000_8.1.e000204.27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3311","article-title":"T cell-induced CSF1 promotes melanoma resistance to PD1 blockade","volume":"10","author":"Neubert","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025100303202800000_8.1.e000204.28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cei.13283","article-title":"Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma","volume":"197","author":"Nyakas","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"2025100303202800000_8.1.e000204.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2025100303202800000_8.1.e000204.30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/labinvest.2016.132","article-title":"Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation","volume":"97","author":"Mandal\u00e0","year":"2017","journal-title":"Lab Invest"},{"key":"2025100303202800000_8.1.e000204.31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0132"},{"key":"2025100303202800000_8.1.e000204.32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18311"},{"key":"2025100303202800000_8.1.e000204.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2005.07.007"},{"key":"2025100303202800000_8.1.e000204.34","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318210ed0e"},{"key":"2025100303202800000_8.1.e000204.35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3356","article-title":"Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay","volume":"11","author":"Berkhout","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025100303202800000_8.1.e000204.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1987-x"},{"key":"2025100303202800000_8.1.e000204.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0250"},{"key":"2025100303202800000_8.1.e000204.38","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.137"},{"key":"2025100303202800000_8.1.e000204.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"},{"key":"2025100303202800000_8.1.e000204.40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025100303202800000_8.1.e000204.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0218-4"},{"key":"2025100303202800000_8.1.e000204.42","first-page":"3870","article-title":"[Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications]","volume":"96","author":"Zhang","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2025100303202800000_8.1.e000204.43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"key":"2025100303202800000_8.1.e000204.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.10.007"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:20:38Z","timestamp":1759486838000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,25]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/jitc-2019-000204"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000204","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}